One of them, the Immunoscore [3], which considers the amount of CD8+ and CD3+ lymphocytes at both the invasive front and central tumor parts of CRCs, has been extensively validated as a prognostic biomarker for CRC [4]. This evidence concerns the gene CD8A and neoplasm.